Q1 FY27 results analysis · July 31, 2026
Glenmark Pharmaceuticals Q1 FY27 Results Analysis: Revenue Surges 23%, Zero Gross Debt Achieved
+930.3%PAT year on year, Rs. 482.83 Cr
Quick summary
Glenmark Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,018.48 Cr (+23.10% YoY) and PAT growth of +930.34% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 4,018.48 Cr (+23.10% YoY) |
| PAT (Q1) | Rs. 482.83 Cr (+930.34% YoY) |
| EBITDA margin | 20.03% (+225 bps YoY) |
| EPS (Q1) | Rs. 17.11 (+930.72% YoY) |
| Market cap | Rs. 63,019.26 Cr |
| CMP | Rs. 2,233.90 |
Quarter Snapshot
Revenue grew 23.1% YoY to a record Q1, EBITDA margin improved 225 bps to 20.03%, but missed the 23% target. Zero gross debt was achieved and Monroe facility restart provides a catalyst, though subsidiary losses remain a drag.
Key Investment Insights
Key Positives
- Revenue of Rs.4,018.48 Cr, highest-ever Q1, grew 23.1% YoY.
- EBITDA margin improved 225 bps YoY to 20.03%.
- PAT of Rs.482.83 Cr (EPS Rs.17.11) on a clean quarter with zero exceptional items.
- Zero gross debt achieved as of FY26, meeting Glenmark 3.0 target.
- Monroe facility cleared VAI status, restarting commercial manufacturing.
- Gross margin stable at ~69% despite API cost inflation.
Risk Factors
- EBITDA margin of 20.03% missed the company's 23% target by ~3pp.
- Subsidiaries were a net drag of Rs.252.81 Cr on consolidated PAT.
- Finance costs rose 26.7% QoQ to Rs.54 Cr, partly due to Nebulizer transaction.
- Cash tax rate of 32.77% is above effective rate of 24.96%, indicating timing differences.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.